What's Happening?
South Africa's human papillomavirus (HPV) vaccination program, initiated in public schools in 2014, has shown substantial success in reducing the prevalence of high-risk HPV types among adolescent girls. The program targeted grade 4 girls aged nine and
older, achieving an initial uptake of approximately 87% for at least one dose. Research conducted through the HPV One and Two Dose Population Effectiveness (HOPE) study in 2019 and 2023 compared HPV prevalence in girls who were too old for the vaccine with those who were eligible. The findings indicate an 83% reduction in infections with HPV types 16 and 18, which are responsible for about 70% of cervical cancer cases globally. This reduction was consistent even among girls living with HIV, a population at higher risk for cervical cancer, where HPV 16/18 infections fell from 29% to 4%. The study also observed cross-protection against genetically related HPV types and evidence of herd protection, benefiting unvaccinated individuals.
Why It's Important?
This development is crucial for public health, particularly in South Africa, which bears a high burden of cervical cancer and HIV. Cervical cancer is a leading cause of illness and death among women worldwide, with over 90% of cases and deaths occurring in low- and middle-income countries. The high prevalence of HIV in South Africa (an estimated 7.9 million people in mid-2025) exacerbates the risk, as HIV increases the likelihood of HPV infection persisting and progressing to cervical disease. The significant reduction in high-risk HPV types provides strong early evidence that future cervical cancer rates will decline, offering a model for other African countries facing similar challenges. The program's success in protecting girls living with HIV is particularly impactful, as this group stands to gain substantially from effective cervical cancer prevention strategies.
What's Next?
While it is too early to measure the program's success solely by cancer rates, as cervical cancer can take decades to develop, continued monitoring will be essential. South Africa adopted a single-dose HPV vaccination approach in October 2024, following the World Health Organization's recommendation to simplify delivery and increase global coverage. Long-term protection, especially among people living with HIV, will require ongoing evaluation. The findings provide compelling evidence for the effectiveness of school-based HPV vaccination programs and could encourage other nations, particularly those in eastern and southern Africa with high HIV and cervical cancer burdens, to implement or strengthen similar initiatives. The observed herd protection also suggests that high vaccination rates can create broader community immunity, further reducing HPV transmission.
Beyond the Headlines
The success of South Africa's HPV vaccination program highlights the profound impact of public health initiatives on preventable diseases. It underscores the importance of sustained vaccination efforts and robust monitoring systems, especially in regions with complex health challenges like high HIV prevalence. The concept of herd protection demonstrated in this study illustrates the collective benefit of individual vaccination, reinforcing the broader societal value of widespread immunization. Ethically, the program addresses health inequities by targeting a disease that disproportionately affects women in low- and middle-income countries and those living with HIV. This success could also influence global health policy, encouraging further investment and implementation of HPV vaccination programs as a key strategy in the fight against cervical cancer worldwide.
